Immune prophylaxis of hepatitis B;Immunprophylaxe der hepatitis B

Zeitschrift fur Gastroenterologie

Volumn 42, Issue 8, 2004, Pages 698-702

  Jilg, Wolfgang ^a   Rink, C ^b   Kallinowski, B ^c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b HELIOS Klinikum Aue   (Germany)

^c Medizinische Klinik und Poliklinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN;

HEPATITIS B; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; REVIEW; SEROCONVERSION; TREATMENT INDICATION;

ANTIBIOTIC PROPHYLAXIS; CONSENSUS; GERMANY; HEPATITIS B; HUMANS; IMMUNOTHERAPY; PATIENT CARE MANAGEMENT; PRACTICE GUIDELINES; PROGNOSIS; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 4444295927     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-813440     Document Type: Review

References (41)

1. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert-Koch-Institut/Stand Juli 2002. Epidem Bull 2002; 28: 227-242 (IV)
2. Virushepatitis B und C bis zum Jahr 2001. Epidem Bull 2002; 44: 369-373 (IV)
3. Seaworth B, Drucker J, Starling J et al. Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis 1988; 157: 332-337 (III)
4. Thierfelder W, Meisel H, Schreier E et al. Die Prävalenz von Antikörpern gegen Hepatitis-A-, Hepatitis-B- und Hepatitis-C-Viren in der deutschen Bevölkerung. Gesundheitswesen 1999; 61 (Sonderheft 2): S110-S114 (Ib)
5. Jilg W, Hottenträger B, Weinberger K et al. Prevalence of markers for hepatitis B in the adult German population. J Med Virol 2001; 63: 96-102 (Ib)
6. Coates T, Wilson R, Patrick G et al. Hepatitis B vaccines: Assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther 2001; 23: 392-403 (Ia)
7. Hadler SC, Francis DP, Maynard JE et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315: 209-214 (Ib)
8. Jilg W, Schmidt M, Deinhardt F. Four-year experience with a recombinant hepatitis B vaccine. Infection 1989; 17: 70-76 (IIa)
9. West DJ, Calandra G. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996; 14: 1019-1027 (III)
10. Wainwright RB, Bulkow LR, Parkinson AJ et al. Protection provided by hepatitis B vaccine in a Yupik escimo population - results of a 10-year study. J Infect Dis 1997; 175: 674-677 (IIa)
11. Anonymous. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000; 355: 561-565 (IV)
12. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2000; 19: 877-885 (III)
13. Wismans PJ, van Hattum J, Mudde GC et al. Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response. J Hepatol 1989; 8: 236-240 (IIa)
14. Resti M, Azzari C, Manelli F et al. Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections indicated? Vaccine 1997; 12/13: 1338-1340 (IIb)
15. Da Villa G, Pellicia MG, Peluso F et al. Anti-HBs responses in children vacinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine. Res Virol 1997; 148: 109-114 (IIb)
16. Watson B, West DJ, Chilkatowsky A et al. Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine. Vaccine 2001; 19: 3164-3168 (IIb)
17. Liao SS, Li RC, Li H et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine 1999; 17: 2661-2666 (IIb)
18. Whittle H, Jaffar S, Wansbrough M et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 2002; 325: 569-574 (IIa)
19. Wismans P, van Hattum J, Stelling T et al. Effect of supplementary vaccination in healthy non-responders to hepatitis B vaccination. Hepatogastroenterol 1988; 35: 78-79 (IIb)
20. Jilg W, Schmidt M, Deinhardt F. Impfversager nach Hepatitis B-Impfung: Effekt zusätzlicher Impfungen. Dtsch Med Wschr 1990; 115: 1545-1548 (IIb)
21. Clemens R, Sänger R, Kruppenbacher J et al. Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule - results of a postmarketing surveillance. Vaccine 1997; 15: 349-352 (IIb)
22. Hasselhorn HM, Kralj N, Hofmann F et al. [Non- and low-response after preventive hepatitis B vaccination]. Gesundheitswesen 1997; 59: 321-328(III)
23. Rendi-Wagner P, Wiedermann G, Stemberger H et al. New vaccination strategies for low- and non-responders to hepatitis B vaccine. Wien Klin Wochenschr 2002; 114: 175-180(III)
24. Cardell K, Fryden A, Normann B. Intradermal hepatitis B vaccination in health care workers. Response rate and experiences from vaccination in clinical practise. Scand J Infect Dis 1999; 31: 197-200 (IIb)
25. Carlsson T, Struve J, Sonnerborg A et al. The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination. Scand J Infect Dis 1999; 31: 93-95 (IIa)
26. Henderson EA, Louie TJ, Ramotar K et al. Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers. Infect Control Hosp Epidemiol 2000; 21: 264-2649 (Ib)
27. Rahman F, Dahmen A, Herzog-Hauff S et al. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 2000; 31: 521-527(IIb)
28. Anonymous. Immunisation against hepatitis B. Lancet 1988; i: 875-876(IV)
29. Bruguera M, Rodicio JL, Alcazar JM et al. Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients. Vaccine 1990; Suppl: S47-S49 (IIa)
30. Marangi AL, Giordano R, Montanaro A et al. Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination. Am J Kidney Dis 1994; 23: 537-542 (IIb)
31. Mitwalli A. Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. Nephron 1996; 73: 417-420 (IIb)
32. Rosman AS, Basu P, Galvin K et al. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. Am J Med 1997; 103: 217-222 (Ib)
33. Mettang T, Schenk U, Thomas S et al. Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure. A preliminary study. Nephron 1996; 72: 192-196 (III)
34. Propst T, Propst A, Lhotta K et al. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis 1998; 32: 1041-1045 (III)
35. Charest AF, McDougall J, Goldstein MB. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am J Kidney Dis 2000; 36: 976-982 (Ib)
36. Kapoor D, Aggarwal SR, Singh NP et al. Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients. J Viral Hepat 1999; 6: 405-409 (Ib)
37. Anandh U, Bastani B, Ballal S. Granulocyte-macrophage colony-stimulating factor as an adjuvant to hepatitis B vaccination in maintenance hemodialysis patients. Am J Nephrol 2000; 20: 53-56 (Ib)
38. Evans TG, Schiff M, Graves B et al. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination. Clin Nephrol 2000; 54: 138-142 (Ib)
39. Looney RJ, Hasan MS, Coffin D et al. Hepatitis B immunization of healthy elderly adults: relationship between naive CD4 + T cells and primary immune response and evaluation of GM-CSF as an adjuvant. J Clin Immunol 2001; 21: 30-36 (Ib)
40. André F, Zuckerman AJ. Review: Protective efficacy of hepatitis B vaccines in neonates. J Med Virol 1994; 44: 144-151 (III)
41. Mitsui T, Iwano K, Suzuki S et al. Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: comparison with immune globulin without vaccine in historical controls. Hepatology 1989; 10: 324-327 (III)